Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 5
2005 9
2006 5
2007 5
2008 2
2009 6
2010 8
2011 10
2012 22
2013 28
2014 36
2015 36
2016 29
2017 44
2018 45
2019 58
2020 70
2021 68
2022 64
2023 57
2024 55
2025 49
2026 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

677 results

Results by year

Filters applied: . Clear all
Page 1
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.
Naing A, Lin CC, Patel MR, Curigliano G, Burris HA, Thistlethwaite F, De Braud F, Minchom A, Ascierto PA, Wake M, Nguyen MA, Abbadessa G, Sainson RCA, Palu CC, Quaratino S, Deantonio C. Naing A, et al. Among authors: ascierto pa. J Immunother Cancer. 2026 Jun 8;14(6):e013540. doi: 10.1136/jitc-2025-013540. J Immunother Cancer. 2026. PMID: 42259602 Free article.
Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers.
Rojas C, Mortier L, Park JJ, Matamala L, Baakili A, Rao S, Xu J, Andrieu L, Wang R, Wang H, Paehler T, Abbadessa G, Ascierto PA. Rojas C, et al. Among authors: ascierto pa. J Immunother Cancer. 2026 May 22;14(5):e014347. doi: 10.1136/jitc-2025-014347. J Immunother Cancer. 2026. PMID: 42173654 Free PMC article. Clinical Trial.
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.
Mandalà M, Chen MF, Sullivan RJ, Sergi MC, Postow M, Lawless AR, Effiom D, Peres T, Lorigan PC, Serra-Bellver P, Dummer R, Amaral T, Rasch ML, Giannarelli D, Vitale MG, Helgadottir H, Robert C, Ubaldi M, Johnson DB, Del Vecchio M, Indini A, Suijkerbuijk KPM, Nathan P, Carter T, Neyns B, Dirven I, Pires da Silva I, Menzies AM, Zimmer L, Livingstone E, Depenni R, Kähler K, Hauschild A, Spagnolo F, Di Giacomo AM, Arance A, Merelli B, Quaglino P, Rossi E, Tucci M, Guida M, Muñoz-Couselo E, Long GV, Larkin J, Ascierto PA. Mandalà M, et al. Among authors: ascierto pa. J Immunother Cancer. 2026 May 4;14(5):e015063. doi: 10.1136/jitc-2026-015063. J Immunother Cancer. 2026. PMID: 42082273 Free PMC article.
Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world study.
Caraglia F, Argenziano G, Scala M, Sparano F, Del Giudice T, Sergi MC, Grimaldi AM, Forte M, Cozzolino S, Colloca A, Esposito A, Giugliano MC, Cioli E, Ottaviano M, Iavarone L, Franco R, Scharf C, Russo A, Cappabianca S, Ascierto PA, Nardone V, Formisano L, Napolitano S, Ciardiello D, Ciardiello F, Troiani T, De Falco V. Caraglia F, et al. Front Immunol. 2026 Apr 16;17:1738772. doi: 10.3389/fimmu.2026.1738772. eCollection 2026. Front Immunol. 2026. PMID: 42079618 Free PMC article.
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.
Schlaak M, Cimminiello C, Pigozzo J, Lee J, Grabbe S, Rutkowski P, Mackiewicz J, Tsai KK, Ascierto PA, Mandalà M, Carnevale-Schianca F, Haferkamp S, Atkinson V, Hassel JC, Sandhu S, Sharfman W, Dean E, Noor U, Iyer S, Rabbie R, Ribas A. Schlaak M, et al. Among authors: ascierto pa. Clin Cancer Res. 2026 Apr 21. doi: 10.1158/1078-0432.CCR-25-3951. Online ahead of print. Clin Cancer Res. 2026. PMID: 42012456
Dissecting the Spectrum of Rare BRAF Mutations in Melanoma: A Nation-Wide Study by the Italian Melanoma Intergroup (IMI).
Dalmasso B, Scaini MC, Cendron L, Rodolfo M, Mattavelli I, Tamborini E, Collina F, Ferrara G, Madonna G, Cota C, Melucci E, Tommasi S, Ubaldi M, Depenni R, Carugno A, Marconcini R, Orgiano L, Lombardo M, Sola S, Pellegrini C, Castiglione F, Gasparotto M, Jorkesh A, Pellegrini S, Raposio E, Boutros A, Tanda ET, Guida M, Quaglino P, Palmieri G, Massi D, Ascierto PA, Spagnolo F, Mandalà M, Menin C, Ghiorzo P, Pastorino L; Italian Melanoma Intergroup. Dalmasso B, et al. Pigment Cell Melanoma Res. 2026 May;39(3):e70087. doi: 10.1111/pcmr.70087. Pigment Cell Melanoma Res. 2026. PMID: 42003243 Free PMC article.
Translating ctDNA into cutaneous melanoma care: An international expert survey.
Geidel G, Fekade N, Raabe K, Smit DJ, Adam L, Heidrich I, Rünger A, Kött J, Zell T, Amaral T, Ascierto PA, Corrie P, Dummer R, Eggermont A, Guo J, Hassel JC, Jalving M, Johnson DB, Kandolf L, Kirkwood JM, Lebbé C, Lee R, Long GV, Lorigan P, Malvehy J, Mangana J, Mohr P, Patel SP, Rizos H, Robert C, Schadendorf D, Sondak VK, Svane IM, Wainstein A, Zager JS, Pantel K, Hauschild A, Gebhardt C; Melanoma World Society Study Group. Geidel G, et al. Among authors: ascierto pa. Eur J Cancer. 2026 May 15;239:116676. doi: 10.1016/j.ejca.2026.116676. Epub 2026 Mar 19. Eur J Cancer. 2026. PMID: 41932032 Free article.
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.
Dummer R, Sandhu S, Miller WH Jr, Butler MO, Taylor MH, Heinzerling L, Blank CU, Couselo EM, Burris HA 3rd, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich AH, Mauch C, Kleha JF, Polli A, Harney AS, di Pietro A, Ascierto PA. Dummer R, et al. Among authors: ascierto pa. Future Oncol. 2026 Apr;22(9):995-1013. doi: 10.1080/14796694.2026.2643481. Epub 2026 Mar 31. Future Oncol. 2026. PMID: 41914670 Free PMC article.
677 results